GO:0007173 epidermal growth factor receptor signaling pathway: Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0007173 describes the molecular signaling cascade initiated by ligand binding to EGFR (ERBB1), a receptor tyrosine kinase on the cell surface.
• The pathway controls proliferation, survival, migration, and differentiation, and is dysregulated in many cancers and persistent infections.
• Core steps include ligand-induced dimerization, autophosphorylation, adaptor recruitment, RAS-MAPK and PI3K-AKT activation, and endocytic trafficking.
• Key genes include EGFR, EREG, GRB2, SOS1, HRAS, RAF1, MAP2K1, MAPK1, PIK3CA, AKT1, and STAT3.
• CRISPR knockout, point mutation, knock-in, and overexpression models enable causal dissection of pathway components.
• The pathway is a major therapeutic target; inhibitors and antibody drugs are used in cancers with EGFR alterations.
Description
The epidermal growth factor receptor signaling pathway (GO:0007173) is a conserved biological process that begins when an extracellular ligand binds to the EGFR (ERBB1) tyrosine kinase receptor on the cell surface. This event triggers receptor dimerization, autophosphorylation, and recruitment of intracellular signaling complexes that propagate signals to the nucleus and other cellular compartments. The pathway is essential for normal development and tissue homeostasis, but its dysregulation is a hallmark of many cancers and contributes to persistent infections. Researchers study GO:0007173 to understand fundamental cell biology and to identify therapeutic targets. The pathway is implicated in glioblastoma, mammary cancer, cervical cancer, and other malignancies, where EGFR overexpression, mutation, or ligand overproduction drive tumor progression. Because of its central role in disease, the pathway is a focus for drug development, including small-molecule inhibitors and monoclonal antibodies. Understanding the precise molecular steps and regulatory mechanisms is critical for designing effective interventions.
epidermal growth factor receptor signaling pathway At A Glance
| GO ID | GO:0007173 |
|---|---|
| GO term | epidermal growth factor receptor signaling pathway |
| Ontology | biological_process |
| Synonym | EGF receptor signaling pathway; ERBB1 signaling pathway; receptor tyrosine-protein kinase erbB-1 signaling pathway |
| Major function | Transduces extracellular EGF-like ligand signals into intracellular responses including proliferation, survival, and migration |
| Key receptor | EGFR (ERBB1), a receptor tyrosine kinase |
| Major downstream cascades | RAS-MAPK, PI3K-AKT, PLC-gamma, and STAT pathways |
| Disease relevance | Dysregulated in multiple cancers and persistent infections |
What Is GO:0007173?
GO:0007173 is defined as the series of molecular signals initiated by binding of a ligand to the tyrosine kinase receptor EGFR (ERBB1) on the surface of a cell, ending with regulation of a downstream cellular process such as transcription. In simpler terms, it is the entire communication chain from an EGF-like ligand outside the cell to changes in gene expression or cell behavior inside the cell.
Why Is epidermal growth factor receptor signaling pathway Important in Cell Biology?
GO:0007173 is critically important because it governs fundamental cellular decisions such as whether a cell divides, survives, migrates, or differentiates. Dysregulation of this pathway is a driving force in many human cancers, including glioblastoma, breast cancer, and cervical cancer, making it a prime therapeutic target. Beyond cancer, EGFR signaling influences immune responses and persistent infections, highlighting its broad physiological relevance. Understanding this pathway at molecular resolution is essential for developing targeted therapies and for interpreting genomic data in precision medicine.
• Controls cell proliferation, survival, and migration in normal development and tissue repair.
• Frequently mutated or overexpressed in cancers such as glioblastoma, breast, and cervical cancer.
• EGFRvIII, a common mutant, drives tumorigenesis in glioblastoma and is a therapeutic target.
• Ligands like EREG amplify EGFR signaling in tumor progression.
• Pathway cross-talk with immune signaling affects persistent infections.
• O-GlcNAcylation regulates EGFR trafficking and signaling, linking metabolism to pathway activity.
• MicroRNAs modulate EGFR pathway components in cervical cancer.
• Targeted inhibitors and antibodies are clinically used, but resistance mechanisms require further study.
• CRISPR screens can identify novel pathway regulators and drug resistance genes.
• Bioinformatics analysis of pathway mutations guides personalized therapy.
What Happens During epidermal growth factor receptor signaling pathway?
Ligand binding and receptor dimerization
In simple terms: An EGF-like ligand binds to EGFR on the cell surface, causing two receptor molecules to pair up.
The pathway begins when ligands such as EGF, TGF-alpha, or EREG bind to the extracellular domain of EGFR (ERBB1). This binding induces a conformational change that promotes receptor dimerization, either with another EGFR molecule (homodimer) or with another ERBB family member (heterodimer). Dimerization is essential for activation of the intracellular kinase domains.
Autophosphorylation and adaptor recruitment
In simple terms: The paired receptors add phosphate groups to each other, creating docking sites for proteins inside the cell.
Upon dimerization, the intrinsic tyrosine kinase activity of EGFR is activated, leading to autophosphorylation of specific tyrosine residues in the cytoplasmic tail. These phosphotyrosine sites serve as docking sites for adaptor proteins such as GRB2, which recruits SOS1, and for enzymes like PLC-gamma and PI3K. This step converts the extracellular signal into an intracellular biochemical signal.
Activation of RAS-MAPK cascade
In simple terms: A relay of proteins passes the signal from the receptor to the nucleus, telling the cell to grow and divide.
The GRB2-SOS1 complex promotes the exchange of GDP for GTP on RAS proteins (HRAS, KRAS, NRAS). Active RAS then recruits and activates RAF1, which phosphorylates MAP2K1 (MEK1), which in turn phosphorylates MAPK1/3 (ERK1/2). Activated ERK translocates to the nucleus and regulates transcription factors such as ELK1 and FOS, driving proliferation and survival gene expression.
PI3K-AKT pathway activation
In simple terms: Another branch of the signal promotes cell survival and growth by activating AKT.
EGFR can directly or indirectly activate PI3K, which generates PIP3 at the membrane, recruiting AKT and PDK1. AKT phosphorylation leads to inhibition of pro-apoptotic proteins and activation of mTOR, promoting cell survival, growth, and metabolism. This branch is frequently hyperactivated in cancers with EGFR mutations.
Receptor internalization and trafficking
In simple terms: After signaling, the receptor is pulled inside the cell to be recycled or degraded, which controls how long the signal lasts.
Activated EGFR is internalized via clathrin-mediated endocytosis and sorted into endosomes. O-GlcNAcylation of EGFR regulates its intracellular trafficking and signaling duration. The receptor can be recycled back to the plasma membrane or targeted to lysosomes for degradation, a process that determines signal amplitude and specificity.
Negative feedback and signal termination
In simple terms: The cell has brakes to shut down the signal, preventing excessive growth.
Negative regulators such as CBL, which ubiquitinates EGFR, and phosphatases like PTPN1/PTP1B, attenuate signaling. Feedback phosphorylation of EGFR by ERK and other kinases reduces sensitivity to ligand. Loss of these brakes contributes to oncogenic signaling.
Key Genes Involved in GO:0007173 epidermal growth factor receptor signaling pathway
The following genes encode core components and regulators of the epidermal growth factor receptor signaling pathway, many of which are recurrently altered in cancer and are prime targets for CRISPR modeling.
| Gene | Major Role | Research Relevance |
|---|---|---|
| EGFR | Receptor tyrosine kinase that initiates the pathway | Mutated/overexpressed in many cancers; primary drug target |
| EREG | Ligand that activates EGFR | Promotes tumor progression; potential biomarker |
| GRB2 | Adaptor protein linking EGFR to RAS activation | Essential for RAS-MAPK signaling; knockout reduces proliferation |
| SOS1 | Guanine nucleotide exchange factor for RAS | Activates RAS; mutations affect pathway output |
| HRAS | Small GTPase transmitting signals from SOS1 | Oncogenic mutations drive tumors; model for pathway activation |
| RAF1 | Serine/threonine kinase activated by RAS | Component of MAPK cascade; target for inhibitors |
| MAP2K1 | Kinase that phosphorylates ERK | Mutations cause developmental disorders and cancers |
| MAPK1 | Effector kinase that translocates to nucleus | Regulates transcription; readout of pathway activity |
| PIK3CA | Catalytic subunit of PI3K | Frequently mutated in cancers; activates AKT |
| AKT1 | Serine/threonine kinase promoting survival | Key survival node; target for therapy |
| STAT3 | Transcription factor activated by EGFR | Drives gene expression; linked to inflammation and cancer |
| PLC-gamma | Phospholipase generating IP3 and DAG | Mediates calcium and PKC signaling |
| CBL | E3 ubiquitin ligase that downregulates EGFR | Negative regulator; loss enhances signaling |
| PTPN1 | Protein tyrosine phosphatase that dephosphorylates EGFR | Attenuates signaling; often dysregulated in cancer |
| CDK4 | Cell cycle kinase downstream of MAPK | Mediates proliferation; target for combination therapy |
| MYC | Transcription factor induced by MAPK | Drives proliferation; frequently overexpressed |
| FOS | Immediate early transcription factor | Readout of MAPK activation |
How Is epidermal growth factor receptor signaling pathway Regulated?
The epidermal growth factor receptor signaling pathway is tightly regulated at multiple levels. Ligand availability and receptor abundance control initiation. Negative feedback loops involving CBL-mediated ubiquitination and phosphatases such as PTPN1 terminate signaling. O-GlcNAcylation of EGFR modulates its intracellular trafficking and signaling duration, linking nutrient status to pathway activity. MicroRNAs can target EGFR or downstream components, adding another layer of regulation. In cancer, these regulatory mechanisms are often disrupted, leading to constitutive pathway activation.
epidermal growth factor receptor signaling pathway and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| EGFR | Glioblastoma, lung cancer, breast cancer | Knockout and point-mutation cell lines to test drug sensitivity |
| EGFRvIII | Glioblastoma | Knock-in of EGFRvIII variant in glioblastoma cells |
| EREG | Tumor progression, poor prognosis | Overexpression and knockout in cancer cell lines |
| PIK3CA | Breast cancer, cervical cancer | Point mutation knock-in to activate AKT signaling |
| STAT3 | Inflammation-associated cancer | Knockout to assess immune modulation |
EGFR signaling in cancer
Dysregulated EGFR signaling is a hallmark of many cancers. In glioblastoma, EGFR amplification and the EGFRvIII mutant drive tumor growth and resistance to therapy. In mammary cancer, EGFR and its ligands promote proliferation and survival, making the pathway a therapeutic target. Cervical cancer cells often overexpress EGFR, and microRNAs that regulate the pathway are being explored as biomarkers. EREG, a ligand for EGFR, is overexpressed in various tumors and correlates with poor prognosis.
EGFR signaling in persistent infections
EGFR signaling has immunological implications in persistent infections. Pathogens can exploit EGFR to modulate host immune responses and promote their survival. Understanding this cross-talk may reveal new strategies to combat chronic infections.
Therapeutic targeting of EGFR pathway
Small-molecule tyrosine kinase inhibitors (e.g., gefitinib, erlotinib) and monoclonal antibodies (e.g., cetuximab) target EGFR signaling in cancers. However, resistance often emerges through secondary mutations or activation of bypass pathways. Combination therapies and next-generation inhibitors are under development.
From epidermal growth factor receptor signaling pathway-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of EGFR reduce proliferation? | CRISPR knockout of EGFR in cancer cell lines |
| Does a specific EGFR mutation confer drug resistance? | Point mutation knock-in of EGFR (e.g., T790M) |
| How does EGFRvIII affect tumor growth? | Knock-in of EGFRvIII in glioblastoma cells |
| What is the role of EREG in tumor progression? | Overexpression and knockout of EREG in cancer cells |
| How does O-GlcNAcylation regulate EGFR trafficking? | Knockout of OGT or O-GlcNAc sites on EGFR |
| Can CRISPR screens identify novel pathway regulators? | Genome-wide CRISPR library screening in EGFR-driven cells |
How to Study the epidermal growth factor receptor signaling pathway Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Transcriptional changes | Identify pathway gene expression signatures |
| Phosphoproteomics | Phosphorylation of signaling proteins | Map active signaling nodes |
| Live-cell imaging | Receptor internalization and trafficking | Study O-GlcNAcylation effects |
| CRISPR knockout screen | Gene essentiality and pathway regulators | Discover novel targets |
| Western blot | Protein expression and phosphorylation | Validate pathway activation |
| Proliferation assay | Cell growth | Assess pathway dependency |
| Bioinformatics pathway analysis | Mutation and expression enrichment | Identify druggable alterations |
Genomic and transcriptomic profiling
RNA-seq and whole-exome sequencing can identify mutations and expression changes in EGFR pathway genes. Bioinformatics analysis of public datasets reveals pathway alterations across cancer types.
Proteomic and phosphoproteomic analysis
Mass spectrometry-based phosphoproteomics quantifies phosphorylation events on EGFR and downstream effectors, providing a snapshot of pathway activity. This helps identify feedback loops and resistance mechanisms.
Imaging and trafficking assays
Fluorescence microscopy and live-cell imaging track EGFR internalization, recycling, and degradation. These methods reveal how O-GlcNAcylation and other modifications affect receptor trafficking.
Functional assays and CRISPR screens
Proliferation, apoptosis, and migration assays measure pathway output. CRISPR knockout and activation screens can systematically identify genes that modulate EGFR signaling and drug response.
How CRISPR Can Be Used to Study GO:0007173 epidermal growth factor receptor signaling pathway
Knockout
CRISPR knockout of EGFR or downstream genes (e.g., GRB2, SOS1) ablates pathway activity, allowing researchers to test dependency and identify synthetic lethal interactions. Knockout cell lines are valuable for drug sensitivity studies.
Point Mutation
Point mutation knock-in can model clinically relevant EGFR mutations (e.g., L858R, T790M) to study drug resistance and altered signaling. This approach helps evaluate next-generation inhibitors.
Knock-in
Knock-in of tagged EGFR (e.g., GFP or HA) enables live-cell imaging and proteomic analysis of receptor trafficking and interactors. Knock-in of EGFRvIII models glioblastoma-specific alterations.
Overexpression
Overexpression of EGFR or its ligands (e.g., EREG) mimics oncogenic amplification and drives tumorigenic phenotypes in cell lines. This is useful for studying ligand-dependent activation and resistance.
How EDITGENE Supports epidermal growth factor receptor signaling pathway Research
Researchers studying epidermal growth factor receptor signaling pathway-related genes often need to determine whether a candidate gene is causally involved in pathway activity, disease progression, or drug response. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for epidermal growth factor receptor signaling pathway research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| CTNNB1 Knockout HCT 116 Cell Line | EDJ-KQ22 | Human | 1499 | Details Get a Quote |
| PIK3CA Knockout Hep-G2 Cell Line | EDJ-KQ40 | Human | 5290 | Details Get a Quote |
| TGFA Knockout HEK293 Cell Line | EDJ-KQ241 | Human | 7039 | Details Get a Quote |
| CTNNB1 Knockout HEK293 Cell Line | EDC07547 | Human | 1499 | Details Get a Quote |
| PRICKLE1 Knockout HEK293 Cell Line | EDJ-KQ323 | Human | 144165 | Details Get a Quote |
| MAPK1 Knockout HEK293 Cell Line | EDJ-KQ390 | Human | 5594 | Details Get a Quote |
| MAPK3 Knockout HEK293 Cell Line | EDJ-KQ391 | Human | 5595 | Details Get a Quote |
| ADAM17 Knockout HEK293 Cell Line | EDC07796 | Human | 6868 | Details Get a Quote |
| AKT1 Knockout HEK293 Cell Line | EDJ-KQ446 | Human | 207 | Details Get a Quote |
| PIK3CA Knockout HEK293 Cell Line | EDJ-KQ518 | Human | 5290 | Details Get a Quote |
| SOCS5 Knockout HEK293 Cell Line | EDJ-KQ528 | Human | 9655 | Details Get a Quote |
| PLCG1 Knockout HEK293 Cell Line | EDJ-KQ582 | Human | 5335 | Details Get a Quote |
| AREG Knockout HEK293 Cell Line | EDJ-KQ607 | Human | 374 | Details Get a Quote |
| ERBB3 Knockout HEK293 Cell Line | EDJ-KQ654 | Human | 2065 | Details Get a Quote |
| ERBB4 Knockout HEK293 Cell Line | EDJ-KQ655 | Human | 2066 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »
Frequently Asked Questions About epidermal growth factor receptor signaling pathway
What is the epidermal growth factor receptor signaling pathway?
It is the series of molecular signals initiated by ligand binding to EGFR (ERBB1) on the cell surface, leading to regulation of downstream cellular processes such as transcription.
What genes are involved in the epidermal growth factor receptor signaling pathway?
Key genes include EGFR, EREG, GRB2, SOS1, HRAS, RAF1, MAP2K1, MAPK1, PIK3CA, AKT1, and STAT3.
What is GO:0007173?
GO:0007173 is the Gene Ontology identifier for the epidermal growth factor receptor signaling pathway, a biological process.
How is EGFR signaling dysregulated in cancer?
EGFR is often mutated, amplified, or overexpressed, leading to constitutive activation of downstream proliferation and survival signals.
What is EGFRvIII?
EGFRvIII is a mutant form of EGFR commonly found in glioblastoma that lacks part of the extracellular domain and signals constitutively.
How can CRISPR be used to study EGFR signaling?
CRISPR knockout, point mutation knock-in, and overexpression models allow researchers to dissect gene function and drug resistance in the pathway.
What are the main downstream pathways of EGFR?
The RAS-MAPK and PI3K-AKT cascades are the primary downstream pathways, along with PLC-gamma and STAT signaling.
What diseases are associated with EGFR signaling?
Cancers such as glioblastoma, breast cancer, and cervical cancer, as well as persistent infections, are associated with dysregulated EGFR signaling.
How is EGFR signaling regulated?
It is regulated by ligand availability, receptor trafficking, negative feedback via CBL and phosphatases, and post-translational modifications like O-GlcNAcylation.
What methods are used to study EGFR signaling?
Common methods include RNA-seq, phosphoproteomics, live-cell imaging, Western blot, and CRISPR screens.
Conclusion
The epidermal growth factor receptor signaling pathway (GO:0007173) is a central biological process that controls cell proliferation, survival, and migration, with profound implications for cancer and infectious diseases. Understanding its molecular mechanisms and regulation is essential for developing targeted therapies. CRISPR-based models and bioinformatics tools are powerful approaches to dissect this pathway and identify new therapeutic targets.
References
- 1. Sabbah DA et al.. 2020. Review on Epidermal Growth Factor Receptor (EGFR) Structure, Signaling Pathways, Interactions, and Recent Updates of EGFR Inhibitors.. Curr Top Med Chem 20(10):815-834 PMID: 32124699
- 2. An Z et al.. 2018. Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies.. Oncogene 37(12):1561-1575 PMID: 29321659
- 3. Levantini E et al.. 2022. EGFR signaling pathway as therapeutic target in human cancers.. Semin Cancer Biol 85:253-275 PMID: 35427766
- 4. Kyriakopoulou K et al.. 2018. Advances in targeting epidermal growth factor receptor signaling pathway in mammary cancer.. Cell Signal 51:99-109 PMID: 30071291
- 5. Hemmat N et al.. 2020. Role of microRNAs in epidermal growth factor receptor signaling pathway in cervical cancer.. Mol Biol Rep 47(6):4553-4568 PMID: 32383136
- 6. Wu L et al.. 2022. O-GlcNAcylation regulates epidermal growth factor receptor intracellular trafficking and signaling.. Proc Natl Acad Sci U S A 119(10):e2107453119 PMID: 35239437
- 7. Mukherjee T et al.. 2019. Immunological implications of epidermal growth factor receptor signaling in persistent infections.. IUBMB Life 71(11):1661-1671 PMID: 31283086
- 8. Cheng WL et al.. 2021. The Role of EREG/EGFR Pathway in Tumor Progression.. Int J Mol Sci 22(23) PMID: 34884633
